Related Experiment Videos
Oxaliplatin-induced immune pancytopenia.
Behrouz Mansouri Taleghani1, Oliver Meyer, Stefano Fontana
1Department of Hematology and Central Hematology Laboratory, Division of Transfusion Medicine, University Hospital, Inselspital, Bern, Switzerland.
Transfusion
|April 26, 2005
Summary
Oxaliplatin chemotherapy can cause severe immune pancytopenia, a rare but serious side effect. This case highlights the risk of drug-induced immune cytopenias in patients receiving oxaliplatin treatment.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Oxaliplatin, a platinum-based chemotherapy agent, is used for colorectal cancer.
- While rare, oxaliplatin has been associated with immune hemolytic anemia and immune thrombocytopenia.
Observation:
- A 79-year-old patient developed severe pancytopenia during oxaliplatin treatment.
- Symptoms included thrombocytopenia, hemolysis, and neutropenia, resolving when oxaliplatin was withheld.
Findings:
- Serologic tests revealed oxaliplatin-dependent antibodies targeting platelets, red blood cells, and neutrophils.
- Platelet-bound antibodies to GPIIb-IIIa, GPIb-IX, and GPIa-IIa were detected.
Implications:
- Oxaliplatin can induce drug-dependent antibodies affecting multiple blood cell lines.
- Clinicians should consider immune cytopenias in patients experiencing cytopenias during oxaliplatin therapy.